Price
No data yet.
Social Signal Score
Analyst Ratings
48 analystsRevenue
$1.21B+222.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Renee D. Gala
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,890
- Beta
- 0.32
- Country
- IE
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.45
Financials
Revenue
$1.21B+222.9%Net Income
$192.80M+121.2%EBITDA
$418.10M+118.8%Free Cash Flow
$397.60M+233.7%EPS (diluted)
$2.78+91.7%Shares Outstanding (diluted)
69.40M+12.3%Operating Expenses
$596.70MCash & Debt
$2.20BReturn of Capital
$0.00Revenue by Segment (annual)
$4.19BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.27B | $-356.15M | $-5.84 |
| 2024 | $4.07B | $560.12M | $9.06 |
| 2023 | $3.83B | $414.83M | $6.55 |
| 2022 | $3.66B | $-224.06M | $-3.58 |
| 2021 | $3.09B | $-328.95M | $-5.51 |
| 2020 | $2.36B | $238.62M | $4.28 |
| 2019 | $2.16B | $523.37M | $9.22 |
| 2018 | $1.89B | $447.10M | $7.45 |
| 2017 | $1.62B | $487.85M | $8.13 |
| 2016 | $1.49B | $396.83M | $6.56 |
| 2015 | $1.32B | $329.54M | $5.38 |
| 2014 | $1.17B | $58.39M | $0.98 |
| 2013 | $872.42M | $216.31M | $3.71 |
| 2012 | $585.98M | $288.59M | $5.09 |
Valuation
JAZZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (21)
- Newsmarketbeat.com·15d ago·Neutral
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsmarketbeat.com·15d ago·Neutral
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Z…
View source ↗ - Newsfool.com·18d ago·Positive
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·33d ago·Neutral
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
View source ↗ - Newszacks.com·33d ago·Neutral
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·34d ago·Neutral
JAZZ Rises on Updated OS Results From Gastric Cancer Study Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
View source ↗ - Newsprnewswire.com·36d ago·Neutral
…are Data submitted for presentation in fourth quarter 2026 For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line trea…
View source ↗ - Newsprnewswire.com·40d ago·Positive
…illion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the…
View source ↗ - Newszacks.com·40d ago·Positive
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
View source ↗ - Newsbenzinga.com·40d ago·Negative
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals The U.S. Food and Drug Administration (FDA), on Tuesday, approved Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
View source ↗ - Newsprnewswire.com·41d ago·Positive
… $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") to qualified …
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
View source ↗ - Newsmarketbeat.com·41d ago·Neutral
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA Jazz Pharmaceuticals NASDAQ: JAZZ outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA.
View source ↗ - Newsprnewswire.com·41d ago·Negative
…Company to host investor webcast on Aug. 25 at 4:30 p.m. ET For U.S. media and investors only DUBLIN, Aug. 25, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoro…
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash positio
View source ↗ - Newsreuters.com·57d ago·Positive
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that has no approved therapies.
View source ↗ - Newsprnewswire.com·57d ago·Negative
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have en
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $6.44 per share
Typical surprise +1.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$5.71 vs $6.18miss
- Tue, May 5$6.34 vs $4.64beat
- Tue, Feb 24$6.64 vs $6.52beat
- Wed, Nov 5$8.13 vs $5.95beat
- Tue, Aug 5$-8.25 vs $-6.12miss
- Tue, May 6$1.68 vs $4.51miss
Estimates and results for JAZZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JAZZ officers and directors.
- Bought
- —
- Sold
- $32.9m
0 trades
28 trades
- Patil Neena Msold
- Gala Renee Dsold
- Cozadd Bruce Csold
- Iannone Robertsold
- Iannone Robertsold
- Iannone Robertsold
- Iannone Robertsold
- Iannone Robertsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Oct 14, 2022 (18d later)Sell$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Nov 5, 2021 (17d later)Buy$1,001 - $15,000
- Bill Floreshouse · TX17 · disclosed Aug 12, 2019 (28d later)Buy$15,001 - $50,000
- Carlos Curbelohouse · FL26 · disclosed Sep 25, 2018 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.